L. F. Omnes
Articles
Cost-Effectiveness of Rituximab in Treatment of Diffuse Large B-Cell Lymphoma
March 1st 2002Rituximab (Rituxan), when combined with CHOP (cyclophosphamide [Cytoxan, Neosar], doxorubicin HCl, vincristine [Oncovin], prednisone) chemotherapy (R-CHOP) in the treatment of patients with CD20-positive diffuse large B-cell lymphoma (DLCL), significantly prolongs event-free and overall survival (GELA [Groupe d’Etude des Lymphomes de l’Adulte] LNH 98-5 study). Our objective was to estimate the cost-effectiveness of R-CHOP based on the evidence currently available.
Latest Updated Articles
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Published: August 19th 2019 | Updated: November 22nd 2024
A 22-Year-Old Woman With Pain, Tenderness and Swelling in the Breast
Published: July 29th 2015 | Updated: November 22nd 2024
Liver Abnormality in 28-Year-Old Patient
Published: November 8th 2024 | Updated: November 22nd 2024
The Hidden Danger Unveiling the Connection Between Multiple Myeloma and Pleural Effusion
